ZENEO® Midazolam : Treatment in epileptic seizure
Epilepsy is a neurological disorder that knows no age limit. According to the WHO, it is one of the most frequent neurological pathologies, affecting approximately 50 million people worldwide.
Estimates suggest that in the European Union, between 2,270 and 7,000 deaths from epilepsy could be prevented every year (1).
Beyond the social stigma they produce, epileptic seizures present at least a physical risk for the patient (injuries to the tongue, risk of fractures or trauma from falls, etc.) and they can cause severe neurological damage if they last longer than five minutes.
Currently, there is no practical treatment to stop a seizure in an adult before the arrival of a medical professional, who will most frequently administer diazepam or midazolam in an intravenous injection. Intramuscular midazolam is recommended as a first-line treatment by the American Epilepsy Society (2).
If that treatment could be deployed by a person accompanying the patient, complications and perhaps hospitalization could be avoided. ZENEO® Midazolam will enable just that. It acts in an average of 1.2 minutes, rapidly stopping the seizure.
Its use will radically change the management of epileptic seizures. Furthermore, the needle-free auto-injector enables total autonomy for patients and thus preserves their quality of life.
(1) Tomson T, Walczak T, Sillanpaa M, Sander JW. Sudden unexpected death in epilepsy: a review of incidence and riskfactors. Epilepsia. 2005;46Suppl 11:54-61.
(2) Tracy Glauser, Shlomo Shinnar, David Gloss, et al., Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Currents: Janvier/Février, Vol. 16, No. 1, pp. 48-61.
When experiencing an epileptic seizure, another person could administer ZENEO® Midazolam for the patient, in a ventrogluteal injection.